Filing Flows › Immunome (IMNM) › Stock forecast & fair value
Immunome (IMNM) stock forecast and price target
Immunome (IMNM) trades at $18.71. 15 analysts' median price target is $36.00 (+92%), from $24.00 to $40.00.
Immunome's latest quarter
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IMNM stock?
The median of 15 analysts' 12-month targets is $36.00, +92% from $18.71; the range is $24.00 to $40.00. The average rating is strong buy.
Does Immunome usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is IMNM stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.